Ganie Mohd Ashraf, Chowdhury Subhankar, Suri Vanita, Joshi Beena, Bhattacharya Prasanta Kumar, Agrawal Sarita, Malhotra Neena, Sahay Rakesh, Rozati Roya, Jabbar Puthiyaveettil Khadar, Sreenivas Vishnubhatla, Sriwastva Mukesh, Wani Imtiyaz Ahmad, Singh Shalini, Sharma Radhey Shyam
Department of Endocrinology & Clinical Research, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India.
Department of Endocrinology & Metabolism, Institute of Postgraduate Medical Education & Research, Kolkata, India.
JMIR Res Protoc. 2021 Aug 27;10(8):e23437. doi: 10.2196/23437.
There is scanty data in India on polycystic ovary syndrome (PCOS) from several small, undersized, convenience-based studies employing differing diagnostic criteria and reporting varied regional prevalence. It is difficult to draw clear-cut conclusions from these studies; therefore, the present multicentric, well-designed, large-scale representative countrywide epidemiological study on PCOS across India was conceived with the aim to generate the actual prevalence rates of PCOS in India with a total sample size of approximately 9000 individuals.
The primary objectives of the study are to estimate the national prevalence of PCOS in India and the burden of comorbidities and to compare the variation in efficacy of standard therapeutic modalities for metabolic dysfunction in women with PCOS.
This multicentric umbrella study consists of three different substudies. Substudy 1 will involve recruitment of women aged 18-40 years using a multistage sampling technique from randomly selected polling booths across urban and rural areas to estimate national prevalence, phenotypic variation, and risk factors among regions. Substudy 2 involves recruitment of subjects from the community pool of substudy 1 and the institutional pool for quantitation of comorbidities among women with PCOS. Substudy 3, an interventional part of the study, aims for comparison of variation in efficacies of common treatment modalities and will be conducted only at 2 centers. The eligible consenting women will be randomized in a 1:1 ratio into 2 arms through a blinding procedure. All these women will undergo clinical, biochemical, and hormonal assessment at baseline and at 3 and 6 months. The data generated will be analyzed using the reliable statistical software SPSS (version 26).
The study is ongoing and is likely to be completed by April 2022. The data will be compiled and analyzed, and the results of the study will be disseminated through publications.
The Indian Council of Medical Research-PCOS study is the first of its kind attempting to provide accurate and comprehensive data on prevalence of PCOS in India.
Clinical Trials Registry-India CTRI/2018/11/016252; ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26366.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/23437.
在印度,关于多囊卵巢综合征(PCOS)的数据较少,这些数据来自几项小型、样本量不足、基于便利性的研究,采用了不同的诊断标准,报告的地区患病率也各不相同。很难从这些研究中得出明确的结论;因此,开展了目前这项在印度全国范围内进行的多中心、设计良好、大规模的PCOS代表性流行病学研究,目的是在约9000名个体的总样本量基础上得出印度PCOS的实际患病率。
本研究的主要目的是估计印度PCOS的全国患病率和合并症负担,并比较PCOS女性代谢功能障碍标准治疗方式疗效的差异。
这项多中心综合研究由三个不同的子研究组成。子研究1将采用多阶段抽样技术,从城乡随机选择的投票站招募18至40岁的女性,以估计全国患病率、表型变异和各地区的风险因素。子研究2从子研究1的社区样本库和机构样本库中招募受试者,以量化PCOS女性的合并症。子研究3是该研究的干预部分,旨在比较常见治疗方式疗效的差异,仅在2个中心进行。符合条件且同意参与的女性将通过盲法程序以1:1的比例随机分为两组。所有这些女性将在基线、3个月和6个月时接受临床、生化和激素评估。生成的数据将使用可靠的统计软件SPSS(版本26)进行分析。
该研究正在进行中,可能于2022年4月完成。数据将进行整理和分析,研究结果将通过出版物发布。
印度医学研究理事会-PCOS研究是同类研究中首个试图提供印度PCOS患病率准确全面数据的研究。
印度临床试验注册中心CTRI/2018/11/016252;ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26366。
国际注册报告识别号(IRRID):DERR1-10.2196/23437。